Reuters logo
BRIEF-Corbus announces last subject enrolled in Phase 2 study of anabasum
May 11, 2017 / 12:31 PM / 6 months ago

BRIEF-Corbus announces last subject enrolled in Phase 2 study of anabasum

May 11 (Reuters) - Corbus Pharmaceuticals Holdings Inc

* Corbus pharmaceuticals announces last subject enrolled in phase 2 study of anabasum for the treatment of skin-predominant dermatomyositis

* Corbus pharmaceuticals holdings inc- company expects topline results from study to be available in q4 of 2017. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below